The evaluation of prehabilitation and nutritional support in cancer patients with neoadjuvant therapy

The evaluation of prehabilitation and nutritional support in cancer patients with neoadjuvant therapy - The evaluation of prehabilitation and nutritional support in cancer patients with neoadjuvant therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040633

Enrollment

Registered

2020-06-03

Start date

2020-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, esophageal cancer, biliary cancer, pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient with cancer(stomach, esophagus, biliary tract, pancreas) who was planned for neoadjuvant therapy.

Exclusion criteria

Exclusion criteria: The patient with low ADL who have difficulty in exercising The patient with dementia The patient who may get worse comorbidities or primary diseases by performing exercise therapy. The patient with severe diabetes The patient with gastrointestinal obstruction The patient who are not scheduled for surgery The patient who was judged by the researcher to be inappropriate for this research.

Design outcomes

Primary

Measure	Time frame
The change of 6 minutes walk test between before and after neoadjuvant therapy	—

Secondary

Measure	Time frame
a) Exercise therapy: 1) Exercise therapy completion rate, 2) Improvement rate of exercise assessment items, 3) Total number of steps per day during the period of exercise therapy 2-a) Improvement rate of walking speed (10m walk) 2-b) Improvement rate of grip strength 2-c) Improvement value of the Simplified Physical Performance Battery (SPPB) 2-d) Improvement value of Timed-up-and-go test (TUG) 2-e) Improvement value of SARC-F Japanese version questionnaire b) Nutritional therapy: 1) Completion rate of nutritional supplements, 2) Average amount of food consumed, 3) Improvement rate of nutritional status assessment items 3-a) Improvement value of MNA-SF 3-b) Improvement rate of upper arm circumference 3-c) Improvement rate of upper arm muscle circumference 3-d) Improvement rate of triceps subcutaneous fat thickness 3-e) Improvement value of CONUT 3-f) Improvement value of PNI 3-g) Improvement value of GNRI c) Chemo(radiation) therapy-related side effects d) Perioperative complications e) Tumor reduction (evaluated by Evans classification) f) Postoperative adjuvant chemotherapy: Rate of postoperative adjuvant chemotherapy, days from surgery to first chemotherapy administration	—

Measure

Time frame

a) Exercise therapy: 1) Exercise therapy completion rate, 2) Improvement rate of exercise assessment items, 3) Total number of steps per day during the period of exercise therapy 2-a) Improvement rate of walking speed (10m walk) 2-b) Improvement rate of grip strength 2-c) Improvement value of the Simplified Physical Performance Battery (SPPB) 2-d) Improvement value of Timed-up-and-go test (TUG) 2-e) Improvement value of SARC-F Japanese version questionnaire b) Nutritional therapy: 1) Completion rate of nutritional supplements, 2) Average amount of food consumed, 3) Improvement rate of nutritional status assessment items 3-a) Improvement value of MNA-SF 3-b) Improvement rate of upper arm circumference 3-c) Improvement rate of upper arm muscle circumference 3-d) Improvement rate of triceps subcutaneous fat thickness 3-e) Improvement value of CONUT 3-f) Improvement value of PNI 3-g) Improvement value of GNRI c) Chemo(radiation) therapy-related side effects d) Perioperative complications e) Tumor reduction (evaluated by Evans classification) f) Postoperative adjuvant chemotherapy: Rate of postoperative adjuvant chemotherapy, days from surgery to first chemotherapy administration

—

Countries

Japan

Contacts

Public ContactKimitaka Tanaka

Hokkaido university hospital Department of gastroenterological surgery 2

kimitaka.t@gmail.com011-706-7714

Outcome results